GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curative Biosciences Inc (OTCPK:CBDX) » Definitions » Gross Margin %

Curative Biosciences (Curative Biosciences) Gross Margin % : 0.00% (As of Mar. 2018)


View and export this data going back to 2004. Start your Free Trial

What is Curative Biosciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Curative Biosciences's Gross Profit for the three months ended in Mar. 2018 was $0.00 Mil. Curative Biosciences's Revenue for the three months ended in Mar. 2018 was $0.00 Mil. Therefore, Curative Biosciences's Gross Margin % for the quarter that ended in Mar. 2018 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Curative Biosciences's Gross Margin % or its related term are showing as below:


CBDX's Gross Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 46.53
* Ranked among companies with meaningful Gross Margin % only.

Curative Biosciences had a gross margin of N/A% for the quarter that ended in Mar. 2018 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Curative Biosciences was 0.00% per year.


Curative Biosciences Gross Margin % Historical Data

The historical data trend for Curative Biosciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curative Biosciences Gross Margin % Chart

Curative Biosciences Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.57 - - - -

Curative Biosciences Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Curative Biosciences's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Curative Biosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curative Biosciences's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curative Biosciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Curative Biosciences's Gross Margin % falls into.



Curative Biosciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Curative Biosciences's Gross Margin for the fiscal year that ended in Jun. 2017 is calculated as

Gross Margin % (A: Jun. 2017 )=Gross Profit (A: Jun. 2017 ) / Revenue (A: Jun. 2017 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Curative Biosciences's Gross Margin for the quarter that ended in Mar. 2018 is calculated as


Gross Margin % (Q: Mar. 2018 )=Gross Profit (Q: Mar. 2018 ) / Revenue (Q: Mar. 2018 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Curative Biosciences  (OTCPK:CBDX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Curative Biosciences had a gross margin of N/A% for the quarter that ended in Mar. 2018 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Curative Biosciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of Curative Biosciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Curative Biosciences (Curative Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
2 South Biscayne Boulevard, Suite 3760, Miami, FL, USA, 33131
Curative Biosciences Inc is a life sciences company focused on developing and commercializing novel therapeutics using hemp-derived CBD. Its products comprise of CBD softgels, Hemp oil, and Topicals.

Curative Biosciences (Curative Biosciences) Headlines

No Headlines